中文名稱:Calcifediol | 英文名稱:Calcifediol |
CAS:19356-17-3 | 品牌: 一研 |
保存條件: Store at -20°C | 產品類別: 抑制劑 |
Cas : 19356-17-3 |
產品屬性:
產品名稱 | 規(guī)格 | CAS號 | 型號 |
Calcifediol | 5mg 25mg 50mg 100mg | 19356-17-3 | EY-Y0163993 |
Cas No.19356-17-3
別名
化學名 (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
分子式 C27H44O2
分子量 400.64
溶解度 ≥ 13.65mg/mL in DMSO
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述:
Vitamin D receptor (VDR) activation is associated with cardiovascular and survival benefits in chronic kidney disease patients. Calcifediol, also known as calcidiol, is a prehormone that is produced in the liver by hydroxylation of vitamin D3.
In vitro: Calcifediol induced CYP24A1 expression with EC50 at 70 nM. Calcifediol stimulated the expression of thrombomodulin with EC50 at 10-100 nM. Confocal microscopy revealed that calcifediol at 0.1 - 10 μM induced VDR translocation into the nucleus dose-dependently; the VDR localization pattern was similar in cells treated with calcitriol [1].
In vivo: Spontaneously hypertensive rats and normotensive Wistar-Kyoto (WKY) rats were injected with either 50 ng/d calcifediol or vehicle alone for 3 days. Decreased calbindin-D9K and cellular Ca2+ flux were observed in control SHR. Calcifediol increased total cell and brush border calbindin-D9K. In contrast, Ca2+ flux, which increased in vit-D animals, remained lower in SHR for plasma calcitriol levels similar to those in WKY rats [2].
Clinical trial: Calcifediol given daily, weekly, or as a single bolus is about 2-3 times more potent in increasing plasma 25(OH)D3 concentrations than vitamin D3. Plasma 25(OH)D3 concentrations of 30 ng/mL were reached more rapidly and reliably with calcifediol [3].
Reference:
[1] Wu-Wong JR, Chen YW, Nakane M, Wolf M. Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes. Cardiovasc Drugs Ther. 2011 Jun;25(3):215-22.
[2] Roullet CM, Roullet JB, Martin AS, McCarron DA. In vivo effect of calcitriol on calcium transport and calcium binding proteins in the spontaneously hypertensive rat. Hypertension. 1994 Aug;24(2):176-82.
[3] Jetter A, Egli A, Dawson-Hughes B, Staehelin HB, Stoecklin E, Goessl R, Henschkowski J, Bischoff-Ferrari HA. Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone. 2014 Feb;59:14-9.
成立日期 | 2014-06-05 (12年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年營業(yè)額 | ¥ 100萬以內 |
主營行業(yè) | 生化試劑,抗體,細胞培養(yǎng),分子生物學,免疫安全 | 經營模式 | 工廠,試劑 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥8000 |
VIP13年
|
湖北威德利化學科技有限公司
|
2025-08-02 | |
詢價 |
VIP4年
|
武漢匠信生物科技有限公司
|
2025-08-02 | |
¥528 |
VIP4年
|
湖北魏氏化學試劑股份有限公司
|
2025-08-02 | |
¥75 |
VIP1年
|
廣東明通生物科技有限公司
|
2025-08-02 | |
¥220 |
VIP6年
|
山東萍聚生物科技有限公司
|
2025-08-02 | |
¥57 |
VIP1年
|
江蘇采薇生物科技有限公司
|
2025-08-02 | |
¥220 |
VIP6年
|
陜西晨明生物科技有限公司
|
2025-08-02 | |
¥75 |
VIP1年
|
山東新雄生物科技有限公司
|
2025-08-02 | |
¥75 |
VIP1年
|
湖北海嘉生物科技有限公司
|
2025-08-02 | |
詢價 |
VIP4年
|
湖北魏氏化學試劑股份有限公司
|
2025-08-02 |